We are live on ! Find out more
MPM BioImpact

MPM BioImpact Portfolio holdings

AUM $1.35B Turnover 42.55%
1-Year Est. Return 172.14%
 

MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.

This Fund
S&P 500
This Quarter Est. Return
-24.96%
1 Year Est. Return
+172.14%
3 Year Est. Return
+619.29%
5 Year Est. Return
+756.25%
10 Year Est. Return
–
AUM
$373M
AUM Growth
-$176M
Cap. Flow
-$17M
Cap. Flow %
-4.55%
Top 10 Hldgs %
67.37%
Holding
38
New
5
Increased
4
Reduced
17
Closed
1
Avg Time Held
0.9 years
Top 10 Avg Time Held
1.1 years
Top 20 Avg Time Held
1 year

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
CGEM icon
1
Cullinan Therapeutics
CGEM
$617M
$80.1M 21.49%
7,648,268
– –
2021 Q1
4 quarters
ITOS icon
2
DELISTED
iTeos Therapeutics
ITOS
$56.2M 15.08%
1,745,943
-98,784
-5% -$3.59M
2020 Q3
6 quarters
MRUS icon
3
DELISTED
Merus
MRUS
$24.3M 6.52%
919,482
-7,820
-0.8% -$210K
2020 Q2
7 quarters
RPTX icon
4
DELISTED
Repare Therapeutics
RPTX
$23.4M 6.27%
1,639,849
– –
2020 Q2
7 quarters
HARP
5
DELISTED
Harpoon Therapeutics
HARP
$15.9M 4.26%
319,671
– –
2019 Q4
9 quarters
NTLA icon
6
Intellia Therapeutics
NTLA
$1.37B
$11.6M 3.11%
159,409
-1,118
-0.7% -$94.7K
2021 Q3
2 quarters
HOWL icon
7
Werewolf Therapeutics
HOWL
$48.2M
$10.5M 2.82%
2,388,011
– –
2021 Q2
3 quarters
BCRX icon
8
BioCryst Pharmaceuticals
BCRX
$1.92B
$10.4M 2.79%
639,089
-22,862
-3% -$367K
2021 Q3
2 quarters
TPTX
9
DELISTED
Turning Point Therapeutics
TPTX
$9.43M 2.53%
351,350
+80,000
+29% +$2.69M
2020 Q1
8 quarters
TCRR
10
DELISTED
TCR2 Therapeutics
TCRR
$9.3M 2.5%
3,370,982
– –
2019 Q4
9 quarters
GERN icon
11
Geron
GERN
$607M
$8.36M 2.24%
6,149,277
+525,388
+9% +$586K
2021 Q3
2 quarters
CYTK icon
12
Cytokinetics
CYTK
$7.2B
$8.25M 2.22%
224,246
-8,022
-3% -$285K
2021 Q3
2 quarters
CRNX icon
13
DELISTED
Crinetics Pharmaceuticals
CRNX
$8.05M 2.16%
366,676
-13,116
-3% -$265K
2021 Q3
2 quarters
TVTX icon
14
Travere Therapeutics
TVTX
$4.77B
$7.16M 1.92%
277,950
-9,943
-3% -$264K
2021 Q3
2 quarters
HRMY icon
15
Harmony Biosciences
HRMY
$1.94B
$6.69M 1.8%
137,517
-4,920
-3% -$201K
2021 Q3
2 quarters
GTHX icon
16
DELISTED
G1 Therapeutics
GTHX
$6.51M 1.75%
856,798
– –
2019 Q4
9 quarters
MIRM icon
17
Mirum Pharmaceuticals
MIRM
$6B
$6.35M 1.71%
288,531
-10,321
-3% -$211K
2021 Q3
2 quarters
RETA
18
DELISTED
Reata Pharmaceuticals
RETA
$5.9M 1.58%
+180,000
New +$5.34M
2022 Q1
0 quarters
YMAB icon
19
DELISTED
Y-mAbs Therapeutics
YMAB
$5.27M 1.41%
443,702
-2,755
-0.6% -$28.3K
2019 Q4
9 quarters
ARQT icon
20
Arcutis Biotherapeutics
ARQT
$3.43B
$4.98M 1.34%
+258,500
New +$4.37M
2022 Q1
0 quarters
ADCT icon
21
ADC Therapeutics
ADCT
$176M
$4.91M 1.32%
334,384
-3,012
-0.9% -$47.8K
2020 Q2
7 quarters
FOLD icon
22
DELISTED
Amicus Therapeutics
FOLD
$4.69M 1.26%
495,603
-17,730
-3% -$166K
2021 Q3
2 quarters
VSTM icon
23
Verastem
VSTM
$970M
$4.58M 1.23%
270,388
-2,240
-0.8% -$38.6K
2021 Q3
2 quarters
ONCR
24
DELISTED
Oncorus
ONCR
$4.23M 1.14%
2,377,031
– –
2020 Q4
5 quarters
AXSM icon
25
Axsome Therapeutics
AXSM
$7.15B
$4.13M 1.11%
99,834
-3,571
-3% -$111K
2021 Q3
2 quarters

Similar funds

MPM BioImpact's Q1 2022 Portfolio in Review

As of Q1 2022, MPM BioImpact held 38 positions worth $373M, down 32% from $549M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

MPM BioImpact withdrew a net $17M in Q1 2022, closing 1 position and reducing 17 holdings. Its most notable exit was Lite Strategy, an estimated $33M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, MPM BioImpact opened a new position in Reata Pharmaceuticals worth $5.9M.

  • MPM BioImpact's largest Q1 2022 buy was Reata Pharmaceuticals: 180,000 shares worth $5.9M.
  • MPM BioImpact added most to Turning Point Therapeutics in Q1 2022, an estimated $2.69M increase.
  • MPM BioImpact's biggest Q1 2022 reduction was iTeos Therapeutics, cutting an estimated $3.59M.
  • MPM BioImpact fully exited Lite Strategy in Q1 2022, selling an estimated $33M.
  • MPM BioImpact's ten largest holdings make up 67% of its $373M portfolio in Q1 2022.
  • MPM BioImpact opened 5 new positions and closed 1 in Q1 2022.
  • MPM BioImpact's portfolio value fell 32% quarter-over-quarter to $373M.

Based on MPM BioImpact's 13F filing for Q1 2022, filed 13 May 2022.